Through this FOA, the NCI encourages administrative supplement applications from awardees who hold eligible awards (as specified in this FOA) so that they can augment efforts on population-based research projects that address critical knowledge gaps in the understanding of rare cancers. Investigators must be able to complete projects within one calendar year.
Applications that will be supported by this initiative must have the following attributes:
- Provide additional value to the underlying study (i.e., support the addition of novel specific aims related to rare cancers);
- Adequate statistical power to investigate hypothesis(es);
- Justification for the selection of cancer type(s);
- Leverage existing data and/or biospecimens to address hypothesis(es); and
- Propose a realistic scope of work, given the limited time and budget requested.
Special consideration will be given to applications involving studies of the following:
- Rare cancers with increasing incidence or mortality rates.
- Rare cancers for which there are known disparities in incidence or mortality rates. Disparities can be by race/ethnicity; religion; socioeconomic status; age; mental health, cognitive, sensory, or physical disability; sexual orientation or gender identity; geographic location; or another characteristic historically linked to discrimination or exclusion.
- Studies of rare cancers in understudied populations. An understudied population is defined as a specific group who may or may not be medically underserved or socially disadvantaged but whose epidemiologic data on cancer health risks and outcomes are currently limited. [For more information, see Martin DN et al. Recommendations for Cancer Epidemiologic Research in Understudied Populations and Implications for Future Needs. Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):573-80].
- Studies of highly lethal or recalcitrant cancers (defined in the Recalcitrant Cancer Research Act of 2012 as having a 5-year survival rate less than 20% and estimated to cause deaths of 30,000 individuals in the United States per year; for more information, go to https://www.gpo.gov/fdsys/pkg/PLAW-112publ239/pdf/PLAW-112publ239.pdf).
Note that studies of rare subtypes of common cancers are not appropriate and are not encouraged.